Description

Overview

CJC-1295 No DAC + Ipamorelin combines two research compounds that act through different upstream pathways of growth-hormone release. “CJC-1295 No DAC” is commonly used in the research market to describe a short-acting modified GHRH(1-29)-type analog, while ipamorelin is a ghrelin/growth-hormone-secretagogue receptor agonist. The scientific rationale is complementary signaling at the pituitary: one component activates the GHRH receptor and the other activates GHSR. Evidence for each mechanism exists, but data on the exact Apex commercial blend should not be assumed from studies of CJC-1295 with DAC or from the individual ingredients alone.

Components

• CJC-1295 No DAC: Short-acting GHRH-receptor agonist research material used to study pituitary GH release. It should be distinguished from long-acting CJC-1295 with DAC.
• Ipamorelin: Selective GHSR/ghrelin-receptor agonist studied for growth-hormone secretagogue pharmacology and endocrine pulse dynamics.

How the Components Work Together

• GHRH receptor pathway: The CJC/modified-GRF component acts through pituitary GHRH receptors.
• GHSR pathway: Ipamorelin acts through the growth-hormone-secretagogue/ghrelin receptor.
• Complementary pituitary signaling: Research interest centers on whether concurrent upstream signals alter GH pulse amplitude or timing compared with either pathway alone.

Research Areas

• Growth-hormone pulse physiology
• GHRH receptor signaling
• Ghrelin/GHSR signaling
• Combination endocrine pharmacology

Research / Study Context

• CJC-family research: Human studies of long-acting CJC-1295 demonstrate GHRH-receptor pharmacology, but those data are not identical to No-DAC material.
• Ipamorelin pharmacology: Human and preclinical studies demonstrate GHSR-mediated growth-hormone release and endocrine selectivity.
• Exact-combination evidence: Robust controlled human evidence for the exact CJC-1295 No DAC + Ipamorelin commercial blend is limited; present component evidence separately.

Key Research Findings

• The components act through distinct but converging pituitary pathways.
• Direct evidence for the exact blend is weaker than evidence for the individual mechanisms.
• Do not describe the blend as clinically proven for anti-aging, fat loss, muscle growth, or recovery.

Scientific Reference Starter Set

• Peptide Education Hub: CJC-1295 + Ipamorelin profile (secondary reference)
• PubMed search: CJC-1295 GHRH analog healthy adults
• PubMed search: ipamorelin selective growth hormone secretagogue